Nikos Pekiaridis | Lightrocket | Getty Images
Moderna has more to supply beyond its Covid vaccine.
The biotech company Wednesday announced positive clinical trial data on three experimental vaccines against other viruses. The corporate is moving those shots to final stage studies, it said.
The update brings Moderna a step closer to having multiple products in the marketplace, which it badly needs amid plunging demand for Covid shots worldwide. The corporate’s Covid jab is its only commercially available product.
Moderna’s stock has long been tied to that vaccine, with shares falling nearly 45% last yr. But shares of the corporate rose greater than 3% in premarket trading Wednesday after the announcements.
Moderna will chart its post-Covid future Wednesday during its fifth annual “Vaccines Day,” an investor event in Boston focused on the corporate’s vaccine portfolio.
That business has an estimated total addressable market of $52 billion for infectious disease shots, which incorporates $27 billion for respiratory vaccines and greater than $25 billion for latent shots and other jabs.
A category of viruses called latent viruses linger inside patients for prolonged periods without causing any symptoms but can “reactivate” and cause serious health complications later of their lives. They represent an enormous unmet need that Moderna can address, Moderna CEO Stéphane Bancel told CNBC in an interview on Wednesday.
“Once those viruses are in your body, it’s in your body perpetually,” he said, adding that there aren’t any approved shots for several of the latent viruses, including several that Moderna is targeting.
The corporate will present recent clinical trial data on the three vaccines, including some against latent viruses, on the event Wednesday.
Those vaccines include a shot against norovirus, a highly contagious stomach bug that causes vomiting and diarrhea; a vaccine against Epstein-Barr virus, a standard herpes virus that may cause contagious infections and is related to some cancers; and a shot designed to focus on a virus that causes shingles and chickenpox.
Moderna may also discuss other updates across its vaccine business. The corporate has five other shots in late-stage clinical trials and said it expects to release data on two of those jabs this yr. That features its combination vaccine against Covid and the flu and a shot against one other common herpes virus called cytomegalovirus, or CMV.
Among the many other vaccines in late-stage development is a jab against respiratory syncytial virus, or RSV, which is predicted to win regulatory approval within the U.S. in May.
It also features a recent and improved version of Moderna’s Covid shot. The corporate on Tuesday said its “next-generation” Covid shot triggered a stronger immune response against the virus than its current vaccine in the marketplace in a late-stage clinical trial.
One other shot in phase three trials is the corporate’s flu vaccine.
Also on Wednesday, Moderna said it recently entered into a development and commercialization funding agreement with Blackstone Life Sciences, a personal equity segment of The Blackstone Group. Blackstone will fund as much as $750 million to advance Moderna’s flu shot program, with “a return based on business milestones” and low single-digit royalties.
Bancel told CNBC the corporate’s messenger RNA platform, utilized in its Covid vaccine, “is working so well” against other diseases. That mRNA technology works by teaching the body to provide a harmless piece of a virus, which triggers an immune response against certain diseases.
“Think concerning the [total addressable market] Moderna goes after – we will be one of the vital vaccine corporations on the earth,” he said.
Still, it’s going to take time before Moderna’s pipeline pays off.
The corporate in its third-quarter earnings release in November said it expects revenue to fall to $4 billion in 2024 before it grows again in 2025. It expects to interrupt even in 2026, executives said during a November earnings call.
Recent clinical trial data on three vaccines
Moderna’s latest shots to maneuver into late-stage trials represent significant opportunities for the corporate.
There may be currently no approved shot to forestall norovirus, probably the most common explanation for the stomach flu. The virus ends in roughly 200,000 deaths per yr and substantial health-care costs, in response to Moderna.
The corporate examined two different norovirus shot candidates in a phase one trial on greater than 600 patients ages 18 to 49 and 60 to 80 within the U.S.
An interim evaluation showed that a single dose of a trivalent vaccine called mRNA-1403 targeting three norovirus strains triggered a robust immune response across all dose sizes. The shot also had a “clinically acceptable” safety profile.
Moderna said it’s moving that shot to a phase three trial. The marketplace for norovirus vaccines represents a $3 billion to $6 billion annual market, in response to the corporate.
Grace Cary | Moment | Getty Images
There are also no shots currently approved to forestall Epstein-Barr virus. It accounts for greater than 90% of cases of infectious mononucleosis, a contagious infection often known as mono, which may cause fever, sore throat and chronic fatigue.
Each the virus and mono are related to a better risk of certain cancers. The virus also increases a patient’s risk of developing multiple sclerosis by 32-fold, in response to Moderna.
“It’s a giant issue for teenagers. There are sometimes kids who should redo a yr of highschool or college, which is a giant waste of your life,” Bancel said. “But it surely has also been related to multiple sclerosis, which is a terrible disease affecting mostly women … so we expect we could prevent that.”
Moderna has been developing two shots designed to tackle multiple conditions related to Epstein-Barr virus. That features a shot designed to forestall mono called mRNA-1189, which is able to move to a phase three study after positive early stage trial data.
A phase one trial examined that vaccine in patients 12 to 30 years old within the U.S. The study found that the shot produced an immune response against mono and was overall well tolerated across all dose sizes.
Bancel said the corporate believes the Epstein-Barr virus might be “a several billion dollar market.”
Varicella-Zoster virus causes each chickenpox and shingles. Older adults have declining immunity against that virus, making them more vulnerable to developing painful, itchy and blister-like rashes. About 1 in 3 adults within the U.S. will develop shingles in some unspecified time in the future of their lives, in response to the Centers for Disease Control and Prevention.
Moderna studied its vaccine against the virus, mRNA-1468, in an early to mid-stage trial on healthy adults ages 50 and older within the U.S.
The shot caused a robust immune response at one month after the second dose and was generally well tolerated by patients, in response to the corporate. Additional data from that ongoing trial might be available later this yr.
Moderna estimates that the marketplace for Varicella-Zoster virus could possibly be $5 billion to $6 billion annually.